Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Neurodegeneration in Alzheimer’s Disease Mice Model 5xFAD
Neural Plasticity · 2025
DOI: 10.1155/np/9880933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neural Plasticity, 2025. Verfasst von Evgenii Gerasimov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Neurodegeneration, Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, …. Hauptthemen laut MEDLINE: Alzheimer Disease, Astrocytes, Hippocampus, Clozapine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of Russian Federation, Ministry of Science and Higher Education of the Russian Federation.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder characterized by Aβ‐amyloid accumulation and cognitive decline. Despite extensive research, effective treatments remain elusive. Astrocytes, the most abundant glial cells, play a crucial role in synaptic transmission, neuronal excitability, and plasticity. In AD, astrocytes become reactive, exhibiting aberrant calcium signaling and altered neurotransmitter release, making them promising targets for disease‐modifying therapies. To address this, we explored designer receptors exclusively activated by designer drugs (DREADDs), specifically the hM3D(Gq) receptor, which selectively modulates intracellular Ca 2+ levels in astrocytes upon activation by clozapine‐N‐oxide (CNO). Using daily CNO administration in 8‐month‐old 5xFAD mice, we observed a significant enhancement of impaired long‐term potentiation formation, accompanied by cognitive improvements in the fear conditioning (FC) and Morris water maze (MWM) tests. Additionally, anxiety levels and social preference deficits in 5xFAD mice were fully restored following astrocytic activity modulation. Importantly, this approach reduced Aβ‐amyloid plaque burden and demonstrated a trend toward mitigating astrocytic reactivity, further highlighting its therapeutic potential. Our findings suggest that targeting astrocytic activity via Gq‐coupled receptors represents a novel and promising strategy for AD treatment, offering a noninvasive and effective approach to mitigating disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Neurodegeneration, Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, St. Petersburg 195251, Russia.
- Laboratory of Molecular Neurobiology, Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg 199034, Russia.
ORCID-Profile: Evgenii Gerasimov, Anastasia Bolshakova, Ilya Bezprozvanny, Olga Vlasova
Förderung
- Ministry of Science and Higher Education of Russian Federation
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Gerasimov, E., Berg, M., Bolshakova, A., Bezprozvanny, I., & Vlasova, O. (2025). Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Neurodegeneration in Alzheimer’s Disease Mice Model 5xFAD. Neural Plasticity. https://doi.org/10.1155/np/9880933
Vancouver
Gerasimov E, Berg M, Bolshakova A, Bezprozvanny I, Vlasova O. Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Neurodegeneration in Alzheimer’s Disease Mice Model 5xFAD. Neural Plasticity. 2025. doi:10.1155/np/9880933
BibTeX
@article{Gerasimov2025,
author = {Gerasimov, Evgenii and Berg, Maria and Bolshakova, Anastasia and Bezprozvanny, Ilya and Vlasova, Olga},
title = {Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Neurodegeneration in Alzheimer’s Disease Mice Model 5xFAD},
journal = {Neural Plasticity},
year = {2025},
doi = {10.1155/np/9880933}
}
EUVIMED